NCT00817492

Completed

Sleep Disturbances as a Non-Traditional Risk Factor in Chron...

University of Chicago Source

Compare

Other study identifiers

Sponsor study identifier

#14747A

Secondary identifiers

5R01DK071696

NIH

Study Type

observational

Actual enrollment (reported)

89

Locations

1 country

Sites

1

Timeline

Study Start

July 2006

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

June 2011

Actual (reported)

Study Completion

June 2011

Actual (reported)

Brief Summary

This study will help determine the relationship between impaired sleep and chronic kidney disease, specifically to determine if sleep disturbances are a risk factor for worsening kidney function.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 89 participants
Study completion date: June 2011
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
July 2006
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
January 5, 2009
Actual (reported)
First Posted
January 6, 2009
Actual (reported)
Primary Completion
June 2011
Actual (reported)
Study Completion
June 2011
Actual (reported)

Last Updated: September 5, 2013
Status Verified: September 2013
Last Update Submitted: September 4, 2013

Conditions

Chronic Kidney Disease

Keywords

SleepCKDkidneyPSGpolysomnographyDecreased sleep timeDecreased sleep quality

Outcome Measures

Primary Outcomes (1)

Sleep Quality
Sleep Quality was determined after PSG on all subjects were completed

Study Arms (2)

1

Subjects with mild to moderate kidney disease

2

Healthy Control Subjects

Eligibility Criteria

Age21 Years - 74 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Renal Clinic patients at The University of Illinois at Chicago Hospital

You may qualify if:

CKD subjects will be participants in a larger study, CRIC, at the University of Illinois, Chicago

Sponsors & Collaborators

University of Illinois at Chicago
Othercollaborator
University of Chicago
Otherlead

Study Sites (1)

The University of Illinois at Chicago

Chicago, Illinois, United States

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Eve Van Cauter, PhD
University of Chicago
PRINCIPAL INVESTIGATOR
James Lash, MD
University of Illinois at Chicago
PRINCIPAL INVESTIGATOR

Enrollment

89 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

January 5, 2009

First Posted

January 6, 2009

Study Start

July 2006

Date type not reported

This date has not been verified as actual or estimated.

NCT00750295

A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis

Phase 1/2Completed

NCT00368017

Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease

Phase 2Terminated

NCT00974532

Analysis of Calcium Balance in Chronic Kidney Disease

Not ApplicableCompleted

NCT00394576

Assessing Novel Methods of Improving Patient Education of Nutrition

Not ApplicableCompleted

NCT00381121

University of Michigan "Nephrology Research BioBank"

Recruiting

NCT00308971

Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)

Phase 2Completed

Healthy controls age and gender matched to 30 CKD subjects, regular bedtimes of at least 6h/night, sedentary lifestyle

You may not qualify if:

Diabetes
Current or previous dialysis for more than 1 month
Uncontrolled hypertension
Heart failure
Liver disease
HIV
Hemoglobin \< 10.5 g/dl
Treatment with EProcrit, Epogen, or Aranesp
Bone or organ transplant,
Use of immunosuppressive drugs within past 6 months
Current oral contraceptive use
Current pregnancy
Chemotherapy for malignancy within past 2 years

Contact the study team to confirm eligibility.

Primary Completion

June 2011

Actual (reported)

Study Completion

June 2011

Actual (reported)

Last Updated

September 5, 2013

Record last verified: 2013-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00817492
Data provider: ClinicalTrials.gov
Source updated: 2013-09-05
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:38:34 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

1

2

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations